In this study we examined the incidence, timing, and reasons for treatment termination in patients with RA treated with gold, penicillamine, or SAS for up to five years.
, and 163 with penicillamine. They comprised all those treated in our department with these drugs between January 1973 and July 1984. Risks of treatment termination for all reasons were similar for each drug at five years (gold 92%, penicillamine 83%, SAS 81%). The risk of treatment termination due to inefficacy was less for gold (29.5%) than for penicillamine (38-1%) or sulphasalazine (41.2%). Adverse effects, however, led to withdrawal of gold in 57%, penicillamine in 41-2%, and SAS in 37%; the most effective drugs appeared most toxic. Serious adverse effects were much more common in association with gold (17-4%) and penicillamine (12-3%) than with SAS (1.6%). Sulphasalazine appears as well tolerated over long periods in RA as gold or pencillamine and is associated with fewer serious adverse effects; of these drugs, it might therefore be considered the agent of first choice.
Many patients with rheumatoid arthritis (RA) need second line drugs but few continue to take them for the long periods necessary to make a significant impact on the disease.' The two drugs most often studied in this respect have been gold and pencillamine. Sulphasalazine (SAS) has also been found to have the properties associated with second line drugs. [2] [3] [4] There have been two studies of long term treatment with SAS, one a comparison with gold, penicillamine and dapsone over two years5 and the other a comparison with gold over three and a half years.6 Both studies suggested that SAS shares with gold and penicillamine the problems of premature treatment withdrawal, though possibly to a lesser degree and for different reasons.
In this study we examined the incidence, timing, and reasons for treatment termination in patients with RA treated with gold, penicillamine, or SAS for up to five years. Yates's correction was applied to test for differences in sex, rheumatoid factor positivity, concurrent corticosteroid therapy, and the proportion of patients receiving prior treatment with other disease modifying therapy. Ranked analysis of variance was used to compare age, duration of disease at onset of therapy, initial serum C reactive protein, and erythrocyte sedimentation rate (ESR) since these data were not normally distributed.
Sulphasalazine, enteric coated, was started at a dose of 0-5 g daily, increasing by 0-5 g weekly to a maintenance of 2 g daily in most patients, though higher doses (2-5-3-0 g) were used in some. Initially, 177 the penicillamine dose was 125 mg daily, increasing by 125 mg increments at two to three month intervals to a maximum of 750 mg daily; maintenance was usually between 375 and 500 mg daily. Sodium aurothiomalate was given at a dose of 50 mg weekly for 20 weeks and then 50 mg on alternate A oco0
weeks for approximately one year; thereafter 50 mg monthly. All patients were also treated with a non-steroidal anti-inflammatory drug (NSAID) and in some cases (Table 1) Patients treated with gold had had RA for a shorter time than those treated with penicillamine (p<0-01) and sulphasalazine (p<0-01). Fewer patients treated with SAS were receiving concurrent corticosteroid therapy (p<0-05). Ranked analysis of variance showed no significant differences between the three groups for ESR, though serum CRP in the gold group was significantly higher than in the two other groups (p<0.01). The frequency of previous disease modifying therapy with either gold, sulphasalazine, penicillamine, dapsone, levamisole, or chloroquine was assessed for each group (Table 2) . With SAS and gold similar proportions of patients had received this therapy as the first to fifth disease modifying drug. Patients treated with penicillamine had more frequently received previous disease modifying therapy before inclusion in the study (p<O-Ol). Fig. 1 shows the incidence of treatment termination for all reasons for the three drugs. By six months 39% patients taking SAS, 36% penicillamine, and 43% gold had stopped treatment. At two years the proportions were 68% with SAS, 69% penicillamine, and 77% gold. The curves become flatter thereafter and between two and five years only a further 13% patients stopped SAS, 14% penicillamine, and 15% gold. Thus by five years 81% patients had stopped SAS, 83% penicillamine, and 92% gold. The median time of treatment termination (when 50% of those who were to stop treatment within five years had done so) was six to seven months for SAS and gold and seven to eight months for penicillamine. Fig. 2 shows termination incidence curves for treatment failure. By two years 33% patients had stopped SAS, 27% penicillamine, and 20% gold. Between two and five years, withdrawals due to treatment failure increased more slowly and there was no change in the relative order of the drugs.
Small but roughly equal proportions of patients (gold 5%, penicillamine 4%, SAS 3%) stopped treatment with each drug within five years because of improvement. Fig. 3 shows treatment termination due to adverse effects. Relatively few adverse reactions led to withdrawal of treatment later than 24 months; by five years 37% of patients had stopped SAS, 41-2% penicillamine, and 57% gold. In patients taking SAS the curve for treatment termination was steepest during the first six months (Fig. 3) (Fig. 4) . Gastrointes between two and three months. Haematological adverse effects led to withdrawal of 1-4% patients.
With gold (Fig. 5) Table 3 . With SAS five serious adverse reactions (four haematological, one cutaneous) were encountered during treatment of 317 patients. One patient developed neutropenia (total white cell count 2*4x109/l with less than 11% polymorphs), but recovery occurred within eight days of stopping treatment. Three patients had severe anaemia. In two it was megaloblastic and haemoglobin fell to 7-7 g/dl (77 g/l) and 6-9 g/dl (69 g/l) respectively. In the first patient serum folate was <10 jsg/l (normal range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] More adverse reactions were classified as serious with gold and penicillamine than with SAS (Table  3) . Predominant were proteinuria and haematuria, and four patients receiving gold and three receiving penicillamine developed a nephrotic syndrome. Five cases of thrombocytopenia were encountered during gold treatment and five during penicillamine therapy. One patient receiving gold developed hypogammaglobulinaemia, four had exfoliative dermatitis, one interstitial pneumonitis, and one an anaphylactic reaction to injection of the first dose.
Discussion
Several factors influenced our choice of particular disease modifying therapy. During the early part of the study gold was usually our drug of first choice. Later, we more often chose SAS since we had evidence that this drug had a more favourable safety profile. These factors explain in part the finding that patients treated with penicillamine had more frequently received previous therapy with other disease modifying drugs, and it is possible that this might have had an unfavourable effect on treatment outcome. A substantial number of patients in each group, however, had already had some other disease modifying drug ( Table 2 ). The differences between groups with respect to sex, disease duration, and seropositivity seem to us unlikely to have influenced drug tolerance. Although more patients treated with gold and penicillamine were receiving therapy with corticosteroids than those treated with sulphasala- dermatitis (4) haematuria (19) pneumonitis (1) Hypogammaglobulinaemia (1) Nephrotic syndrome (4) Anaphylaxis (1) zine, steroid doses were small and were not changed. The effect of low dose corticosteroids on treatment outcome is unknown, though in one study steroids did not influence the rate of gold withdrawal. 10 Comparisons of drugs also depend on uniform methods of assessing their efficacy. We used one subjective and two objective criteria: the 'clinical score', ESR, and serum C reactive protein. These three assessments together compare favourably with other 'process' measurements of rheumatoid activity.p Life-table analysis as a method of displaying data has been explored by Richter et al, 11 and we felt it to be the most appropriate means of depicting the reasons for treatment termination with each drug since it displays graphically both the time and cumulative importance of each. It SAS is known to stress folate metabolism.'2 13 In a prospective study, however, SAS did not appear to cause folate deficiency in rheumatoid patients. 14 The causes of anaemia in the other two patients are uncertain and their relation to SAS in doubt.
For both gold and penicillamine the frequency and type of adverse reactions are in accord with general experience."' 15-21 Our finding of 10-8% termination of penicillamine for dysgeusia is higher than found in most previous reports, though the incidence of this complication is up to 33%. l Our patients were told that taste alteration or loss was likely to be temporary but many would not tolerate the symptom.
No previous studies have considered the treatment of RA with SAS for periods up to five years. In the only other long term study 49% patients stopped taking SAS by two years6; our figure for the same period was 68%. We cannot satisfactorily explain the difference, but in both studies withdrawal was due mainly to nausea, dizziness, and dyspepsia. It is uncertain whether these are central effects of sulphapyridine or local gastric intolerance, or both. Gastrointestinal side effects of SAS appear to be more common in RA than in inflammatory bowel disease22 perhaps because of the additive effects of NSAIDs in RA and because of difficulty in distinguishing some drug and disease effects in inflammatory bowel disease.
We have investigated whether our performance with these three drugs has improved by comparison with our The data show that there is little difference between SAS, gold, and penicillamine when judged either by the frequency of treatment termination due to adverse effects or by inefficacy within five years. Since sulphasalazine was least often associated with serious adverse effects it is now our first choice when initiating disease modifying therapy for RA.
